title: Transcatheter arterial chemoembolization with fine-powder cisplatin-lipiodol for HCC.
abstract: OBJECTIVE
  Fine-powder cisplatin has recently been developed, allowing the easy manufacture of high-density cisplatin-lipiodol suspensions. The aim of this study is to evaluate the efficacy and toxicity of transcatheter arterial chemoembolization (TACE) with fine-powder cisplatin and lipiodol suspension against advanced hepatocellular carcinoma (HCC).
  
  
  METHODS
  We prospectively analyzed 20 patients (16 men, 4 women) with inoperative advanced HCC without extrahepatic metastases who underwent TACE with fine-powder cisplatin and lipiodol suspension in our hospital between August 2006 and December 2008. All patients were administered a suspension of fine-powder cisplatin at 10 mg/1 cm of tumor diameter.
  
  
  RESULTS
  Partial response was seen in 10 cases, with stable disease in 7 cases and progressive disease in 3 cases. Overall response rate was 50%. The 1-year survival rate was 90%. Adverse effects (> or = grade 3) occurred in 40%, with vomiting in 5%, thrombocytopenia in 15%, elevated serum bilirubin in 20%, decreased serum albumin in 5%, fever in 65%, general fatigue in 15% and anorexia in 30%. However, no other life-threatening, adverse events were observed.
  
  
  CONCLUSIONS
  TACE with fine-powder cisplatin suspended in lipiodol provides better therapeutic efficacy, suggesting the potential usefulness of this agent in the treatment of advanced HCC.
authors.affiliation: Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
authors.forename: Yohei
authors.initials: Y
authors.lastname: Koizumi
authors.forename: Masashi
authors.initials: M
authors.lastname: Hirooka
authors.forename: Takahide
authors.initials: T
authors.lastname: Uehara
authors.forename: Yoshiyasu
authors.initials: Y
authors.lastname: Kisaka
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Uesugi
authors.forename: Teru
authors.initials: T
authors.lastname: Kumagi
authors.forename: Masanori
authors.initials: M
authors.lastname: Abe
authors.forename: Bunzo
authors.initials: B
authors.lastname: Matsuura
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Hiasa
authors.forename: Morikazu
authors.initials: M
authors.lastname: Onji
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D004998:Ethiodized Oil / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011208:Powders
chemical_list: D000970:Antineoplastic Agents; D011208:Powders; D004998:Ethiodized Oil; D002945:Cisplatin